JHL Biosimilar Pipeline

Molecule
Potential Indication / Disease Area
Description
Status

JHL1211
(Biosimilar Omalizumab)

Allergic Asthma, Chronic Idiopathic Urticaria

A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE)

Pre-Clinical Stage (complete MCB/WCB)

Click to read more on JHL1211 (Omalizumab)

JHL1211 is a proposed biosimilar to omalizumab, which is marketed by Genentech under the trade name Xolair®.

Omalizumab is a monoclonal antibody therapy used for Chronic idiopathic urticaria (CIU; chronic hives without a known cause) in patients 12 years of age and older, moderate to severe persistent allergic asthma in patients 6 years of age or older not controlled by inhaled corticosteriods.

JHL1199
(Biosimilar Pertuzumab)

Inflammatory carcinoma of the breast, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer (MBC), Stage I Breast Carcinoma

A recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of HER2.

Pre-Clinical Stage (MCB/WCB in progress)

Click to read more on JHL1199 (Pertuzumab)

JHL1199 is a proposed biosimilar to pertuzumab, which is marketed by Genentech under the trade name Perjeta®.

Pertuzumab is a monoclonal antibody used prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive) and used after surgery (adjuvant treatment) in people with HER2-positive early breast cancer that has a high likelihood of coming back.

JHL1266
(Biosimilar Denosumab)

Osteoporosis, Bone CancerBone Loss, Bone pain, Fracture Bone, Spinal Cord Compression, Bone destruction, Giant cell tumor of the bone, High risk of fracture, Refractory Hypercalcemia of malignancy

A novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL)

Pre-Clinical Stage (Selecting Clone in progress)

Click to read more on JHL1266 (Denosumab)

JHL1266 is a proposed biosimilar to denosumab, which is marketed by Amgen under the trade name Prolia® and Xgeva®.

Denosumab is a monoclonal antibody therapy used for treatment of a range of osteoporosis, Colorectal cancer (CRC).

JHL1152 
(Biosimilar Ipilimumab)

Late-Stage Melanoma

A cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody.

Pre-Clinical Stage (Selecting Clone in progress)

Click to read more on JHL1152 (Ipilimumab)

JHL1152 is a proposed biosimilar to ipilimumab, a cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody.

JHL1255 
(Biosimilar Ustekinumab)

Psoriasis, Crohn’s Disease

Human monoclonal antibody that is directed against interleukin 12 and interleukin 23

Pre-Clinical Stage (Selecting Clone in progress)

Click to read more on JHL1255 (Ustekinumab)

JHL1255 is a proposed biosimilar to ustekinumab, a human monoclonal antibody that is directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.

JHL1178 
(Biosimilar Ramucirumab)

NSCLC, GC,CRC

Human IgG1 that binds to VEGFR2

Pre-Clinical Stage (Selecting Clone in progress)

Click to read more on JHL1178 (Ramucirumab)

JHL1178 is a proposed biosimilar to ramucirumab, a human IgG1 that binds to VEGFR2, which in turn blocks the natural ligands secreted by tumors, therefore can inhibit tumor angiogenesis.

Interested in working with us?

JHL is open for partnerships and license agreements for its biosimilar assets worldwide. We can offer you access to our expertise in process development, manufacturing and regulatory management.